Major revision per component

Cemented primary TKA
Uncemented primary TKA

Knee » Survival » Major revision per component » Cemented primary TKA

TABLE Cumulative major revision percentages of cemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2020 (n=245,342)

					Cumulative revision percentage Kaplan Meier (95% CI)
Femur component	Tibia component	Total primary TKAs (n)	Median (IQR) age (yr)	Major revision¹ arthroplasties (n)	1yr	3yr	5yr	7yr	10yr	12yr
All cemented TKAs for osteoarthritis		245,342	69 (63-75)	4,861	0.3 (0.3-0.3)	1.5 (1.4-1.5)	2.0 (2.0-2.1)	2.4 (2.3-2.5)	2.9 (2.8-3.0)	3.3 (3.2-3.5)
Genesis II	Genesis II	54,470	69 (62-75)	998	0.4 (0.3-0.4)	1.6 (1.4-1.7)	2.0 (1.9-2.2)	2.3 (2.1-2.4)	2.6 (2.4-2.7)	2.8 (2.5-3.0)
NexGen	NexGen	52,138	69 (63-75)	1,174	0.3 (0.2-0.3)	1.4 (1.3-1.5)	2.1 (1.9-2.2)	2.8 (2.7-3.0)	3.7 (3.4-3.9)	4.3 (4.0-4.7)
Vanguard Complete Knee	Vanguard Complete Knee	41,005	69 (62-75)	635	0.3 (0.3-0.4)	1.3 (1.2-1.4)	1.7 (1.5-1.8)	2.0 (1.8-2.1)	2.3 (2.1-2.5)	2.5 (2.2-2.8)
PFC / Sigma	PFC / Sigma	28,773	70 (63-76)	419	0.3 (0.2-0.3)	1.1 (1.0-1.2)	1.5 (1.3-1.7)	1.7 (1.5-1.8)	1.9 (1.7-2.1)	2.0 (1.8-2.2)
LCS	LCS	16,881	70 (63-76)	515	0.4 (0.3-0.4)	2.3 (2.1-2.6)	3.2 (2.9-3.5)	3.7 (3.4-4.0)	4.3 (3.9-4.6)	4.7 (4.2-5.3)
Triathlon	Triathlon	7,404	70 (64-76)	106	0.4 (0.3-0.6)	1.5 (1.2-1.8)	2.0 (1.6-2.4)	2.4 (1.9-3.0)	n.a.	n.a.
AGC V2	AGC V2	4,420*	71 (65-77)	94	0.1 (0.0-0.2)	1.0 (0.7-1.3)	1.4 (1.1-1.8)	1.8 (1.4-2.2)	2.2 (1.8-2.7)	2.7 (2.1-3.3)
balanSys	balanSys	3,283	69 (62-76)	62	0.2 (0.0-0.3)	1.4 (0.9-1.8)	2.3 (1.7-2.9)	2.6 (1.9-3.3)	2.9 (2.1-3.8)	3.6 (2.4-4.8)
TC Plus	TC Plus	3,278	70 (63-76)	59	0.3 (0.1-0.6)	1.3 (0.9-1.7)	1.9 (1.3-2.4)	2.2 (1.6-2.7)	2.3 (1.7-3.0)	2.6 (1.8-3.4)
Optetrak	Optetrak	3,071*	70 (62-76)	213	0.6 (0.3-0.8)	3.0 (2.3-3.6)	4.2 (3.4-4.9)	5.5 (4.6-6.3)	7.9 (6.8-9.0)	10.3 (8.6-11.9)

¹ Revision of at least the femur or tibia component.
* Denotes prosthesis combinations with no reported use in primary TKAs in 2020.
Please note: n.a. if <50 cases were at risk; TKA: total knee arthroplasty; CI: confidence interval; IQR: interquartile range.

Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

Knee » Survival » Major revision per component » Uncemented primary TKA

TABLE Cumulative major revision percentages of uncemented primary total knee arthroplasties by prosthesis component combination of patients who underwent a TKA for osteoarthritis in the Netherlands in 2007-2020 (n=12,680)

					Cumulative revision percentage Kaplan Meier (95% CI)
Femur component	Tibia component	Total primary TKAs (n)	Median (IQR) age (yr)	Major revision¹ arthroplasties (n)	1yr	3yr	5yr	7yr	10yr	12yr
All uncemented TKAs for osteoarthritis		12,680	69 (62-76)	327	0.6 (0.5-0.7)	2.1 (1.8-2.3)	2.6 (2.3-2.9)	2.9 (2.6-3.2)	3.3 (2.9-3.6)	3.4 (3.0-3.8)
LCS	LCS	8,160	69 (63-76)	194	0.5 (0.4-0.7)	2.0 (1.7-2.3)	2.5 (2.1-2.8)	2.6 (2.2-3.0)	2.8 (2.4-3.2)	2.9 (2.4-3.3)
Triathlon	Triathlon	1,115	70 (63-76)	12	0.4 (0.0-0.7)	0.7 (0.2-1.2)	1.0 (0.3-1.6)	1.4 (0.5-2.3)	2.0 (0.6-3.4)	n.a.
ACS	ACS	494	69 (61-75)	14	1.7 (0.5-2.9)	2.9 (1.3-4.5)	2.9 (1.3-4.5)	3.4 (1.6-5.1)	n.a.	n.a.
Duracon	Duracon	282*	69 (61-77)	4	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.4 (0.0-1.1)	0.4 (0.0-1.1)	1.6 (0.0-3.1)	1.6 (0.0-3.1)
Rotaglide	Rotaglide	265*	69 (61-76)	37	0.4 (0.0-1.1)	6.5 (3.5-9.5)	10.5 (6.7-14.2)	13.1 (8.9-17.2)	14.7 (10.2-19.2)	n.a.
NexGen	NexGen	225	70 (62-77)	9	0.9 (0.0-2.1)	3.0 (0.6-5.4)	3.8 (1.0-6.6)	4.9 (1.4-8.4)	n.a.	n.a.
ACS LD	ACS LD	224*	70 (61-76)	7	0.9 (0.0-2.2)	3.4 (0.9-5.9)	n.a.	n.a.	n.a.	n.a.
Genesis II	Genesis II	201	69 (62-75)	5	0.5 (0.0-1.5)	2.8 (0.4-5.2)	2.8 (0.4-5.2)	2.8 (0.4-5.2)	n.a.	n.a.
Vanguard Complete Knee	Vanguard Complete Knee	156	67 (61-74)	9	1.9 (0.0-4.1)	4.7 (1.3-8.2)	4.7 (1.3-8.2)	4.7 (1.3-8.2)	n.a.	n.a.
Attune	Attune	145	69 (64-73)	2	0.7 (0.0-2.1)	n.a.	n.a.	n.a.	n.a.	n.a.

Results must be interpreted with caution. Patient characteristics like age and diagnosis, as well as procedure characteristics like the experience of the surgeon performing the procedure, femoral head size and articulation of the prosthesis may have influenced the cumulative revision percentages.

This website is only accessable on large screens